## Claims

1. A vaccine composition comprising an antigen and/or antigenic composition, QS21, 3 De-O-acylated monophosphoryl lipid A (3D-MPL) and an oil in water emulsion wherein the oil in water emulsion has the following composition: a metabolisible oil, such as squalene, alpha tocopherol and tween 80.

- 19 -

- 2. A vaccine as claimed in claim 1 wherein the ratio of QS21:3D-MPL is from 1:10 to 10:1.
- 3. A vaccine composition as claimed in claim 1 or 2 capable of invoking a cytolytic T cell response in a mammal to the antigen or antigenic composition.
- 4. A vaccine composition as claimed in any of claims 1 to 3 capable of stimulating interferon γ production.
- 5. A vaccine composition as claimed in any of claims 1 to 4 wherein the ratio of QS21:3D-MPL is from 1:1 to 1:2.5.
- 6. A vaccine composition as claimed herein comprising an antigen or antigenic composition derived from any of Human Immunodeficiency Virus, Feline Immunodeficiency Virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Hepatitis A,B,C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma.
- 7. A vaccine as claimed in any of claim 1 to 5 wherein the antigen is a tumour antigen.
- 8. Use of composition as defined in any of claims 1 to 5 for the manufacture of a vaccine for the prophylatic treatment of viral, bacterial, or parasitic infections.
- 9. Use of composition as defined in any of claims 1 to 5 for the manufacture of a vaccine for the immunotherapeutic treatment of viral, bacterial, parasitic infections or cancer.
- 10. A method of treating a mammal suffering from or susceptible to a pathogenic infection comprising the administration of a safe and effective amount of a composition according to any of claims 1 to 5.

WO 95/17210 PCT/EP94/04246

- 20 -

- 11. A method of treating a mammal suffering from cancer comprising the administration of a safe and effective amount of a composition according to any of claims 1 to 5.
- 12. A process for making a vaccine composition according to claims 1 to 5 comprising admixing QS21, 3D-MPL and the oil in water emulsion as defined in claim 1 with an antigen or antigenic composition.
- 13. A vaccine composition comprising an antigen or antigenic composition in association with an oil in water emulsion which emulsion comprises: a metabolisable oil, alpha tocopherol, and tween 80.